$0.66-0.01 (-0.88%)
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity.
Fractyl Health, Inc. in the Healthcare sector is trading at $0.66 with a market capitalization of $105M. Wall Street consensus targets $5.24 (5 analysts), implying a +689.0% move over the next 12 months. The stock is currently near its 52-week low of $0.38, remaining 39.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunctio...
Fractyl Health, Inc. reported past first quarter 2026 results showing net income of US$9.22 million and earnings of US$0.06 per share from continuing operations, reversing a prior-year loss. A day earlier, the company secured authorization in the Netherlands to begin a Phase 1/2 first-in-human trial of its RJVA-001 GLP-1 gene therapy candidate for type 2 diabetes, positioning Fractyl as a dual clinical-stage player alongside its Revita program. We’ll now examine how the RJVA-001...
Fractyl Health (GUTS) is back on investor radar after reporting first quarter net income of US$9.22 million and securing Clinical Trial Application authorization in the Netherlands for its RJVA-001 gene therapy in type 2 diabetes. See our latest analysis for Fractyl Health. The recent 1 month share price return of 93.53% and 3 month share price return of 130.9% suggest strong short term momentum, even though the 1 year total shareholder return is still down 38.22%. If Fractyl Health's early...
Gainers Quantum Cyber (NASDAQ:QUCY) shares rose 163.0% to $0.85 during Wednesday's regular session. The market value of their outstanding shares is at $4.0 million. Whitehawk Therapeutics (NASDAQ:WHWK) stock moved upwards by 29.59% to $5.08. The company's market cap stands at $193.8 million. As per the news, the Q1 earnings report came out 4 days ago. Replimune Group (NASDAQ:REPL) stock moved upwards by 29.09% to $5.28. The market value of their outstanding shares is at $320.8 million. MaxCyte (
Fractyl Health Inc (GUTS) showcases significant advancements in clinical trials and a robust financial outlook, despite ongoing challenges.
Fractyl Health (NASDAQ:GUTS) said it remains on track to report pivotal data for its Revita therapy in early fourth quarter 2026, as management highlighted clinical, regulatory and reimbursement developments during the company’s first-quarter 2026 earnings call. Chief Executive Officer Dr. Harith R